<DOC>
	<DOCNO>NCT01345136</DOCNO>
	<brief_summary>The purpose study determine RAD001 treatment shrink slow growth vestibular schwannoma ( ) Neurofibromatosis 2 ( NF2 ) patient . Secondary objective include determine RAD001 treatment improve hearing ability NF2 patient . RAD001 oral drug approve Food Drug Administration ( FDA ) type tumor , approve FDA treatment NF2 related tumor .</brief_summary>
	<brief_title>Study RAD001 Treatment NF2-related Vestibular Schwannoma</brief_title>
	<detailed_description>This protocol Phase II , open-label , efficacy safety study single-agent RAD001 patient NF2 . During study , subject receive continuous daily oral treatment RAD001 1 year tumor progression . Primary Objective : To determine whether RAD001 effect VS growth patient NF2 rate sufficient submit drug test . Secondary Objectives : To determine whether RAD001 effect volume intracranial tumor , assess effect RAD001 hearing function patient NF2 ( applicable ) .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neuroma</mesh_term>
	<mesh_term>Neuroma , Acoustic</mesh_term>
	<mesh_term>Neurofibromatosis 2</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Diagnosis NF2 National Institutes Health ( NIH ) criteria Age â‰¥ 16 year Progressive VS growth previous 12 month . WHO performance status &gt; = 2 Adequate bone marrow , liver renal function . For woman childbearing potential , pregnancy breastfeed Willingness ability comply schedule visit , drug administration plan , laboratory test , study procedure , study restriction . Willingness provide informed consent Inability tolerate periodic MRI scan gadolinium contrast . Inability tolerate periodic audiologic test understand language establish score word recognition test . Inability adequately perform volumetric measurement least 1 target lesionNote : Patients cochlear auditory brainstem implant may participate target lesion accurately assess . Radiation therapy target lesion 60 month precede inclusion study . Patients currently receive anticancer therapy receive anticancer therapy within 4 week start study drug . Immunization attenuate live vaccine within one week study entry study period . Presence fungal infection require systemic antifungal treatment enrollment Other malignancy within past 3 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin . Patients severe and/or uncontrolled medical condition . Patients know hypersensitivity everolimus type rapamycin excipients . Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Neurofibromatosis Type 2</keyword>
	<keyword>Vestibular schwannoma</keyword>
	<keyword>Hearing</keyword>
</DOC>